NET Research Foundation Awards Six Grants NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs).The grants fund clinical, translational, and basic research in the United States, Australia, Switzerland, and the United Kingdom. Two of the studies will work towards refining approaches for Peptide Receptor Radionuclide Therapy (PRRT). Other grants focus on developing laboratory models or identifying clinical biomarkers to support drug development. One grant explores a target to inhibit metastasis in pancreatic NETs. All the studies will collectively improve insights for personalized medicine in NETs. (MORE)
| |
|
| Paving the Road Toward Powerful Targeted Therapies
by Effie Tzameli, Ph.D., NETRF Director of Research
The NETRF 2017 Request for Applications was designed to invite innovative and transformative translational and clinical research proposals that would bring us closer to more effective therapies. While we have a longstanding interest in basic research, this year we were also interested in applications that tackle big issues in the field of neuroendocrine tumor research, from novel theranostics and more personalized clinical studies to the new generation of experimental tools for basic and translational research. (MORE)
| |
|
Nuclear Medicine Physician Added as NETRF Scientific Advisor NETRF’s Board of Scientific Advisors welcomes Lisa Bodei, M.D., Ph.D., Director of Targeted Radionuclide Therapy, Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center. The Board of Scientific Advisors helps NETRF identify and review research opportunities. These experts ensure we fund meaningful research with the most potential to affect our understanding of NETs. Dr. Bodei brings broad expertise in nuclear medicine to the group. (MORE)
| |
Learn about Research Opportunities
NETRF offers competitive research grants up to $1.2 million for four years to NET scientists and clinicians all over the world. In late spring 2018, we will issue an open call for competitive letters of intent. Applicants must have a faculty appointment at a recognized research institution. An M.D., Ph.D., or equivalent degree is required. Candidates are not required to have NET research experience (we welcome newcomers to the field). Candidates must, however, demonstrate a commitment to continue with NET research in the future. To be notified of our upcoming grant opportunities, REGISTER HERE.
| |
|
7th Annual Focus on Neuroendocrine TumorsFriday, April 13 – 8 am to 2 pm – Philadelphia, PA The 7th Annual Focus on Neuroendocrine Tumors program, cosponsored by NETRF/Penn Medicine, is designed for those at risk, newly diagnosed, currently in treatment, or survivors of neuroendocrine tumors. Family members and caregivers are also welcome to attend. Penn Medicine experts will offer the latest information on NET treatment, research, and survivorship. Participants will learn about newly approved PRRT treatments, interventional radiology, and surgery. (MORE)
| |
Learn Online: Anywhere, Anytime
Check out the patient educational videos we just posted to the NETRF YouTube channel from our Houston, TX, conference in January. Leading NET experts from MD Anderson Cancer Center discuss the latest NET treatments including PRRT, surgery, immunotherapy, and targeted therapies. Learn from some of the most respected physicians in the world. (MORE)
| |
Donations Bring Researchers TogetherNext month, NETRF will host its 10th Annual NET Research Symposium, an event made possible by generous charitable donations from individuals and family foundations. This scientific event brings together leading NET researchers and clinicians from across the globe. With the goal of increasing collaboration, researchers share data, resources, and ideas for improving the diagnosis and treatment of neuroendocrine cancers. The gathering helped launched multiple studies, including a government-funded clinical trial. See what a difference your support makes. (MORE)
| |
| We are pleased to announce that this eUpdate
is sponsored by Novartis Pharmaceutical Corporation.
| |
|
|
|
|
